RET-altered Solid Tumors
3 clinical trials · Condition
◉ Watch RET-altered Solid Tumors
| Record | Firm | Date |
|---|---|---|
| Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities (NCT04683250) | Taiho Pharmaceutical Co., Ltd. | 2020-12-16 |
| Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (NCT03037385) | Hoffmann-La Roche | 2017-03-17 |
Track RET-altered Solid Tumors automatically
Every clearance here is in the API, with alerts when new ones post.